2215-CL-0304 (R/R)

2215-CL-0304 (R/R)

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)


Study treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link